Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: Analysis of a multicenter, rater-blinded, open-label study-Reference-Cited by-同舟云学术

Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: Analysis of a multicenter, rater-blinded, open-label study

Published:2005-12 Issue:12 Volume:27 Page:1930-1941
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Meyer Jonathan M.,Pandina Gahan,Bossie Cynthia A.,Turkoz Ibrahim,Greenspan Andrew

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference35 articles.

1. Mortality and causes of death in schizophrenia in Stockholm county, Sweden;Osby;Schiz Res,2000

2. Cardiovascular illness and hyperlipidemia in patients with schizophrenia;Meyer,2003

3. Medical Illness and Schizophrenia,2003

4. Cardiovascular morbidity and mortality associated with the metabolic syndrome;Isomaa;Diabetes Care,2001

5. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III);JAMA,2001

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Psychotropic Drug–Related Weight Gain and Its Treatment;American Journal of Psychiatry;2024-01-01

2. Evolutions of Metabolic Parameters Following Switches of Psychotropic Drugs: A Longitudinal Cohort Study;Schizophrenia Bulletin;2022-09-26

3. Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone;Frontiers in Pharmacology;2021-07-14

4. Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients;BMC Psychiatry;2019-02-21

5. The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial;Hormone and Metabolic Research;2018-10-04